TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18 or over~* Histologically proven adenocarcinoma of the prostate (all stages) in whom endocrine treatment was indicated (except neoadjuvant hormonal therapy)~* Has completed Study FE200486 CS07~* Has not met a withdrawal criteria at Visit 9 (day 28) in Study FE200486 CS07

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 120 mg (20 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (20 mg/mL)
- Degarelix 120 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (40 mg/mL)
- Degarelix 160 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 160 mg (40 mg/mL)
- Degarelix 200 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (40 mg/mL)
- Degarelix 200 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (60 mg/mL)
- Degarelix 240 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (40 mg/mL)
- Degarelix 240 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (60 mg/mL)
- Degarelix 320 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 320 mg (60 mg/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Closure of Protective Ileostomy 2 vs. 12 Weeks After TME

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anastomosis ≤ 5cm from anal verge~* age \>18 years~* informed consent~* uneventful course after first operation~Exclusion Criteria:~* pregnancy~* allergy to contrast agent~* severe non-surgical complications~* evident abdominal - pelvic complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 weeks (Type: EXPERIMENTAL): Ileostomy closure after 2 weeks
- 12 weeks (Type: EXPERIMENTAL): Ileostomy closure after 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. No prior treatment for esophageal cancer~2. No prior radiation to the chest or upper abdominal area~3. No prior treatment with an EGFR inhibitor or an anti-angiogenic agent~4. Disease should be limited to the esophagus and regional lymph nodes -~Exclusion Criteria:~1. History of stroke~2. History of heart attack~3. Inadequately controlled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Transcutaneous Electrical Auricular Stimulation of the Vagus Nerve in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients of both live and deceased donors~Exclusion Criteria:~* Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VNS - Live donor kidney recipients. (Type: EXPERIMENTAL): Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
- sham VNS - Live donor kidney recipients. (Type: SHAM_COMPARATOR): Live donor kidney recipients. As above, but without applying any VNS
- VNS - Deceased donor kidney recipients. (Type: EXPERIMENTAL): Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
- sham VNS - Deceased donor kidney recipients. (Type: SHAM_COMPARATOR): Deceased donor kidney recipients. As above, but without applying any VNS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: ESP Block for Laparoscopic Nephrectomy Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring laparoscopic nephrectomy and partial nephrectomy for malignancy~* Patients of age 18 and over~* BMI \< 40~* Patients who are expected to stay in-hospital overnight after surgery~Exclusion Criteria:~* Patient refusal~* Contraindications to paravertebral blocks: Infection at the site of needle insertion, empyema, allergy to local anesthetic drugs, and tumor occupying the thoracic paravertebral space, coagulopathy, bleeding disorder or therapeutic anticoagulation~* Known allergy to local anesthetics~* Inability to provide informed consent~* Inability to use a PCA due to languate or comprehension barriers~* BMI \>= 40~* Any patient on opioids for greater than or equal to 3 months duration prior to surgery~* Patients with chronic pain syndromes~* Donor nephrectomies due to incision location~* Cystic kidney because of very large incisions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound-guided continuous ESP block with opioid PCA (Type: EXPERIMENTAL): A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
- Ultrasound-guided sham block and catheter with opioid PCA (Type: SHAM_COMPARATOR): The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females aged 1.5 years or younger~2. Post menstrual age of 29 weeks or older~3. Patients with suspected or diagnosed necrotizing enterocolitis~4. Patient in the Children's Hospital of Philadelphia (CHOP) neonatal intensive care unit (NICU) or pediatric intensive care unit (PICU)~5. Parental permission~Exclusion Criteria:~1. Medical history of Lumason hypersensitivity~2. Hemodynamic instability as defined by rapid escalation of cardiopulmonary support in the past 12-24 hours, as defined by the clinical care team including ≥ 1 intensive care physician not part of the study team~3. Pulmonary insufficiency as defined by FiO2 requirements of \>40% and/or subjects with pulmonary hypertension requiring nitric oxide

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Months
- Healthy Volunteers: f

Study Arms:
- Contrast-enhanced Ultrasonography (Type: EXPERIMENTAL): Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has completed study treatment in study FE200486 CS02.~* Has completed visit 16 in study FE200486 CS02.~* Has not met any withdrawal criteria up to and including visit 15 in FE200486 CS02

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 80/80 + 40 (Type: EXPERIMENTAL): In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
- Degarelix 40/40 + 40 (Type: EXPERIMENTAL): In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
- Degarelix 80 + 20 (Type: EXPERIMENTAL): In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: FMISO-PET in Brain Tumors and SCS Effect

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pathologically confirmed (first presentation or relapsed) high grade glioma (Grade III or Grade IV according WHO criteria) proposed for radical treatment with 3D radiotherapy and temozolomide.~* Patients 18-75 years old.~* Karnofsky \>= 60% and ECOG =\< 2.~* Signed informed consent.~Exclusion Criteria:~* Clinical or psychological contraindications to fly (if 18F-FMISO-PET is realized in Madrid) or to SCS-placement (only for this subset).~* Pregnant or breastfeeding women and women of fertile age who are not using a safe contraceptive method or do not intend to use one during the trial. Safe contraceptive methods are oral or parenteral contraceptive treatments or barrier methods: masculine or feminine condom, diaphragm and/or intrauterine device (IUD) or withdrawal over the course of the study.~* Serious co-existing or concurrent illness, including any of the following: uncontrolled or severe infection, heart, liver or kidney disease~* Lung thromboembolism.~* Another malignancy in the last 5 years other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~* Patients with life expectancy \<3 months.~* Patients with any of the following: creatinine \> 2 mg/dl, neutrophils \<1.5 \* 10\^9/L, platelets \<100 \* 10\^9/L or hemoglobin \<8.5 g/dL.~* Contraindications to receive radiotherapy or chemotherapy Clinical or psychological contraindications for placement of spinal cord stimulation devices (only for that specific subset of patients).~* Patients who are unable or unwilling to meet the protocol study.~* Patients who do not meet all the inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm-A: 18F-FMISO-PET without SCS (Type: OTHER): One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
- Arm-B: 18F-FMISO-PET without/with SCS (Type: OTHER): Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stress Test on the Prediction of Cardiovascular Events in a High-risk Firefighter Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any professional or volunteer firefighter with a high cardiovascular risk attached to the Departmental Fire and Rescue Service of the Loire who has carried out an effort test between 2006 and 2014.~* Subject who received informed oral information about the study by telephone and agreed to participate in the study~Exclusion Criteria:~* Subject unable to understand the study~* Subject matter subject to a legal protection measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Firefighter (Type: None): Firefighter with high cardiovascular risk

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (≥ 18 years) at the time of signing informed consent form~2. Understand and voluntarily sign informed consent form~3. Able to adhere to study visit schedule and other protocol requirements~4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2~5. Absolute neutrophil count ≥ 1500 / mm³~6. Platelet count ≥ 100,000 / mm³~7. Resectable pancreatic adenocarcinoma~8. Pathologic diagnosis of pancreatic adenocarcinoma~Exclusion Criteria:~1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing informed consent form~2. A history of renal dysfunction (serum creatinine \> 1.8 mg/dL)~3. Presence of active infection~4. Untreated second malignancy~5. Pregnant or breast feeding females (A urine pregnancy test will be obtained in all women of child-bearing age at initial screening prior to study enrollment and administration of chemotherapy.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine / Cisplatin (Type: EXPERIMENTAL): Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary open-angle glaucoma (POAG) in the study eye.~* Pseudophakic with Posterior Chamber IOL (PCIOL)~* Able and willing to attend follow up visits for two years post-operative~* Able and willing to sign informed consent~Exclusion Criteria:~* Phakia or aphakia~* Previous glaucoma procedure with or without an implantable glaucoma device (including incisional surgery, ALT, iridectomy/iridotomy, etc.) \[Subjects with one prior SLT application (\>3 months prior to screening) or prior ECP (performed \> 12 months prior to screening) can be enrolled\].~* Use of more than 3 ocular hypotensive medications (combination medications count as 2 medications)~* Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, pseudoexfoliative, pigmentary or neovascular glaucoma~* Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior synechiae, rubeosis or other angle abnormalities)~* Participation in any clinical trial ≤ 30 days prior to screening

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VISCO360 ab interno canaloplasty surgery (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
- Selective Laser Trabeculoplasty (SLT) (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo the SLT procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent before the initiation of any study related procedures and continues to give willing consent for participation~* Age ≥ 40 years~* Have had upper extremity tremor for \< 3 years duration, regardless of presumed diagnosis or etiology~* Have a UPDRS part III score upon entry of ≤ 16~Exclusion Criteria:~* Any clinically significant or unstable physical or psychological illness based on medical history or physical examination at screening, as determined by the investigator~* Structural brain abnormality affecting the entire brain (e.g., normal pressure hydrocephalus) or the striatum (e.g., local tumor or stroke)~* Any clinically significant abnormal laboratory results obtained at screening and as determined by the investigator~* Any clinically significant abnormal electrocardiogram (ECG) results obtained at screening and as determined by the investigator~* Any history of drug, narcotic, or alcohol abuse within 2 years before the date of informed consent, as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, Fourth Edition, revised (DSM-IV-TR \[American Psychiatric Association, 1994\])~* Positive urine drug screen for opiates, cocaine, or amphetamines at screening~* Positive pregnancy test before imaging~* Participation in an investigational drug or device clinical trial within 30 days before the date of informed consent~* Previous scan with any DAT imaging agent (e.g. \[123I\]NAV5001, Altropane, DaTscan, DOPASCAN)~* Any exposure to radiopharmaceuticals within 30 days before the date of informed consent~* Breast-feeding~* Inability to lie supine for 1 hour~* Any thyroid disease other than adequately treated hypothyroidism~* Known sensitivity or allergy to iodine or iodine containing products~* Treatment within the 30 days before the date of imaging with amoxapine, amphetamine, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline, paroxetine, or citalopram.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAV5001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility